Author:
Cleeland Charles S.,Allen Jeff D.,Roberts Samantha A.,Brell Joanna M.,Giralt Sergio A.,Khakoo Aarif Y.,Kirch Rebecca A.,Kwitkowski Virginia E.,Liao Zhongxing,Skillings Jamey
Publisher
Springer Science and Business Media LLC
Reference84 articles.
1. Centers for Disease Control and Prevention (CDC). Cancer survivors—United States, 2007. MMWR Morb. Mortal. Wkly Rep. 60, 269–272 (2011).
2. Dantzer, R., Meagher, M. W. & Cleeland, C. S. Translational approaches to treatment-induced symptoms in cancer patients. Nat. Rev. Clin. Oncol.
http://dx.doi.org/10.1038/nrclinonc.2012.88
3. Segota, E. & Bukowski, R. M. The promise of targeted therapy: cancer drugs become more specific. Cleve. Clin. J. Med. 71, 551–560 (2004).
4. Fakih, M. & Vincent, M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr. Oncol. 17 (Suppl. 1), S18–S30 (2010).
5. Sankhala, K. et al. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target. Oncol. 4, 135–142 (2009).
Cited by
106 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献